{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:16:38Z","timestamp":1792196198548,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s13318-025-00940-9","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T18:59:22Z","timestamp":1743879562000},"page":"219-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Influence of Polymorphisms in Pharmacokinetics-Related Genes on the Areas Under the Plasma Concentration-Time Curves of Doxorubicin and Doxorubicinol in Patients with Diffuse Large B-Cell Lymphoma Receiving CHOP Therapy"],"prefix":"10.1007","volume":"50","author":[{"given":"Keigo","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenori","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Tachita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4560-6423","authenticated-orcid":false,"given":"Takenori","family":"Niioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"4","key":"940_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/hon.2613","volume":"37","author":"P Mondello","year":"2019","unstructured":"Mondello P, Mian M. Frontline treatment of diffuse large B-cell lymphoma: beyond R-CHOP. Hematol Oncol. 2019;37(4):333\u201344. https:\/\/doi.org\/10.1002\/hon.2613.","journal-title":"Hematol Oncol"},{"issue":"1","key":"940_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13045-020-01011-z","volume":"13","author":"L Wang","year":"2020","unstructured":"Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13(1):175. https:\/\/doi.org\/10.1186\/s13045-020-01011-z.","journal-title":"J Hematol Oncol"},{"issue":"24","key":"940_CR3","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1182\/bloodadvances.2022007609","volume":"6","author":"V Camus","year":"2022","unstructured":"Camus V, Belot A, Oberic L, Sibon D, Ghesqui\u00e8res H, Thieblemont C, Fruchart C, Casasnovas O, Michot JM, Molina TJ, Bosly A, Joubert C, Haioun C, Nicolas-Virelizier E, Feugier P, Fitoussi O, Delarue R, Tilly H. Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. Blood Adv. 2022;6(24):6169\u201379. https:\/\/doi.org\/10.1182\/bloodadvances.2022007609.","journal-title":"Blood Adv"},{"issue":"5669","key":"940_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1136\/bmj.3.5669.503","volume":"3","author":"G Bonadonna","year":"1969","unstructured":"Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F. Clinical evaluation of adriamycin, a new antitumour antibiotic. Brit Med J. 1969;3(5669):503\u20136. https:\/\/doi.org\/10.1136\/bmj.3.5669.503.","journal-title":"Brit Med J."},{"issue":"5","key":"940_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, L\u00f3pez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379\u201391. https:\/\/doi.org\/10.1016\/S1470-2045(06)70664-7.","journal-title":"Lancet Oncol"},{"issue":"4","key":"940_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12012-022-09721-1","volume":"22","author":"M Sheibani","year":"2022","unstructured":"Sheibani M, Azizi Y, Shayan M, Nezamoleslami S, Eslami F, Farjoo MH, Dehpour AR. Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches. Cardiovasc Toxicol. 2022;22(4):292\u2013310. https:\/\/doi.org\/10.1007\/s12012-022-09721-1.","journal-title":"Cardiovasc Toxicol"},{"issue":"12","key":"940_CR7","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","volume":"266","author":"LJ Steinherz","year":"1991","unstructured":"Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266(12):1672\u20137.","journal-title":"JAMA"},{"issue":"8","key":"940_CR8","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.2007.11.8877","volume":"26","author":"PA Ganz","year":"2008","unstructured":"Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin JW, Martino S, Albain KS. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. J Clin Oncol. 2008;26(8):1223\u201330. https:\/\/doi.org\/10.1200\/JCO.2007.11.8877.","journal-title":"J Clin Oncol"},{"key":"940_CR9","doi-asserted-by":"publisher","first-page":"44735","DOI":"10.1038\/srep44735","volume":"7","author":"L Zhao","year":"2017","unstructured":"Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017;7:44735. https:\/\/doi.org\/10.1038\/srep44735.","journal-title":"Sci Rep"},{"issue":"25","key":"940_CR10","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2174\/092986709788803312","volume":"16","author":"C Carvalho","year":"2009","unstructured":"Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267\u201385. https:\/\/doi.org\/10.2174\/092986709788803312.","journal-title":"Curr Med Chem"},{"issue":"11","key":"940_CR11","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869\u201379. https:\/\/doi.org\/10.1002\/cncr.11407.","journal-title":"Cancer"},{"issue":"1","key":"940_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003088-198815010-00002","volume":"15","author":"PA Speth","year":"1988","unstructured":"Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet. 1988;15(1):15\u201331. https:\/\/doi.org\/10.2165\/00003088-198815010-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"940_CR13","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1073\/pnas.85.10.3585","volume":"85","author":"RD Olson","year":"1988","unstructured":"Olson RD, Mushlin PS, Brenner DE, Fleischer S, Cusack BJ, Chang BK, Boucek RJ Jr. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A. 1988;85(10):3585\u20139. https:\/\/doi.org\/10.1073\/pnas.85.10.3585.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"940_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440\u20136. https:\/\/doi.org\/10.1097\/FPC.0b013e32833ffb56.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"940_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/ars.2015.6457","volume":"26","author":"A Jo","year":"2017","unstructured":"Jo A, Choi TG, Jo YH, Jyothi KR, Nguyen MN, Kim JH, Lim S, Shahid M, Akter S, Lee S, Lee KH, Kim W, Cho H, Lee J, Shokat KM, Yoon KS, Kang I, Ha J, Kim SS. Inhibition of carbonyl reductase 1 safely improves the efficacy of doxorubicin in breast cancer treatment. Antioxidants Redox Signal. 2017;26(2):70\u201383. https:\/\/doi.org\/10.1089\/ars.2015.6457.","journal-title":"Antioxidants Redox Signal."},{"issue":"6","key":"940_CR16","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/bcp.13070","volume":"82","author":"JS P\u00e9rez-Blanco","year":"2016","unstructured":"P\u00e9rez-Blanco JS, Santos-Buelga D, Fern\u00e1ndez de Gatta MD, Hern\u00e1ndez-Rivas JM, Mart\u00edn A, Garc\u00eda MJ. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin\u2019s lymphoma. Br J Clin Pharmacol. 2016;82(6):1517\u201327. https:\/\/doi.org\/10.1111\/bcp.13070.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"940_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10637-017-0443-2","volume":"35","author":"K Piska","year":"2017","unstructured":"Piska K, Koczurkiewicz P, Bucki A, W\u00f3jcik-Pszczo\u0142a K, Ko\u0142aczkowski M, P\u0119kala E. Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents. Invest New Drugs. 2017;35(3):375\u201385. https:\/\/doi.org\/10.1007\/s10637-017-0443-2.","journal-title":"Invest New Drugs"},{"key":"940_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113231","volume":"185","author":"LF Pippa","year":"2020","unstructured":"Pippa LF, Oliveira ML, Rocha A, de Andrade JM, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio. J Pharmaceut Biomed Anal. 2020;185: 113231. https:\/\/doi.org\/10.1016\/j.jpba.2020.113231.","journal-title":"J Pharmaceut Biomed Anal."},{"issue":"1","key":"940_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ajco.13776","volume":"19","author":"J Methaneethorn","year":"2023","unstructured":"Methaneethorn J, Tengcharoen K, Leelakanok N, AlEjielat R. Population pharmacokinetics of doxorubicin: a systematic review. Asia-Pacific K Clin Oncol. 2023;19(1):9\u201326. https:\/\/doi.org\/10.1111\/ajco.13776.","journal-title":"Asia-Pacific K Clin Oncol."},{"issue":"2","key":"940_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/bcp.14628","volume":"87","author":"BC Sallustio","year":"2021","unstructured":"Sallustio BC, Boddy AV. Is there scope for better individualisation of anthracycline cancer chemotherapy? Brit J Clin Pharmacol. 2021;87(2):295\u2013305. https:\/\/doi.org\/10.1111\/bcp.14628.","journal-title":"Brit J Clin Pharmacol."},{"issue":"10","key":"940_CR21","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1517\/17425255.2011.610180","volume":"7","author":"D Jamieson","year":"2011","unstructured":"Jamieson D, Boddy AV. Pharmacogenetics of genes across the doxorubicin pathway. Expert Opin Drug Metab Toxicol. 2011;7(10):1201\u201310. https:\/\/doi.org\/10.1517\/17425255.2011.610180.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"21","key":"940_CR22","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.3390\/cancers14215436","volume":"14","author":"AA Bagdasaryan","year":"2022","unstructured":"Bagdasaryan AA, Chubarev VN, Smolyarchuk EA, Drozdov VN, Krasnyuk II, Liu J, Fan R, Tse E, Shikh EV, Sukocheva OA. Pharmacogenetics of drug metabolism: the role of gene polymorphism in the regulation of doxorubicin safety and efficacy. Cancers. 2022;14(21):5436. https:\/\/doi.org\/10.3390\/cancers14215436.","journal-title":"Cancers"},{"issue":"5","key":"940_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00280-023-04580-1","volume":"92","author":"J Nakagawa","year":"2023","unstructured":"Nakagawa J, Takahata T, Chen Y, Saito K, Kamata K, Tachita T, Yamashita S, Saito K, Ueno K, Sato A, Sakuraba H, Niioka T. Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy. Cancer Chemother Pharmacol. 2023;92(5):391\u20138. https:\/\/doi.org\/10.1007\/s00280-023-04580-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"940_CR24","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2174\/138161282005140214165212","volume":"20","author":"YH Choi","year":"2014","unstructured":"Choi YH, Yu AM. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharmaceut Design. 2014;20(5):793\u2013807. https:\/\/doi.org\/10.2174\/138161282005140214165212.","journal-title":"Curr Pharmaceut Design."},{"issue":"5","key":"940_CR25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1177\/10781552231189700","volume":"30","author":"M Mahfouz","year":"2024","unstructured":"Mahfouz M, Alkhalid ZN, Birand N. Determination of drug-drug interaction in breast cancer patients receiving doxorubicin and cyclophosphamide regimen. J Oncol Pharmacy Pract. 2024;30(5):830\u201343. https:\/\/doi.org\/10.1177\/10781552231189700.","journal-title":"J Oncol Pharmacy Pract."},{"issue":"7","key":"940_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/FPC.0b013e328301a869","volume":"18","author":"L Fan","year":"2008","unstructured":"Fan L, Goh BC, Wong CI, Sukri N, Lim SE, Tan SH, Guo JY, Lim R, Yap HL, Khoo YM, Iau P, Lee HS, Lee SC. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics. 2008;18(7):621\u201331. https:\/\/doi.org\/10.1097\/FPC.0b013e328301a869.","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"940_CR27","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1124\/jpet.109.160614","volume":"332","author":"OS Bains","year":"2010","unstructured":"Bains OS, Karkling MJ, Lubieniecka JM, Grigliatti TA, Reid RE, Riggs KW. Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exper Ther. 2010;332(3):755\u201363. https:\/\/doi.org\/10.1124\/jpet.109.160614.","journal-title":"J Pharmacol Exper Ther."},{"issue":"10","key":"940_CR28","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1111\/j.1349-7006.2008.00903.x","volume":"99","author":"S Lal","year":"2008","unstructured":"Lal S, Sandanaraj E, Wong ZW, Ang PC, Wong NS, Lee EJ, Chowbay B. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008;99(10):2045\u201354. https:\/\/doi.org\/10.1111\/j.1349-7006.2008.00903.x.","journal-title":"Cancer Sci"},{"issue":"13","key":"940_CR29","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","volume":"30","author":"JG Blanco","year":"2012","unstructured":"Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia JP, Oeffinger KC, Ritchey AK, Villaluna D, Relling MV, Bhatia S. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes\u2013a report from the Children\u2019s Oncology Group. J Clin Oncol. 2012;30(13):1415\u201321. https:\/\/doi.org\/10.1200\/JCO.2011.34.8987.","journal-title":"J Clin Oncol"},{"issue":"12","key":"940_CR30","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200746120-00005","volume":"46","author":"M Joerger","year":"2007","unstructured":"Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, F\u00e9ty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JHM, EORTC-PAMM-NDDG. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet. 2007;46(12):1051\u201368. https:\/\/doi.org\/10.2165\/00003088-200746120-00005.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"940_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00280-008-0854-z","volume":"64","author":"PA Thompson","year":"2009","unstructured":"Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, Ellis KJ, Renbarger J, Berg SL. Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol. 2009;64(2):243\u201351. https:\/\/doi.org\/10.1007\/s00280-008-0854-z.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3\u20134","key":"940_CR32","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ejps.2010.07.015","volume":"41","author":"DR Barpe","year":"2010","unstructured":"Barpe DR, Rosa DD, Froehlich PE. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharmaceut Sci. 2010;41(3\u20134):458\u201363. https:\/\/doi.org\/10.1016\/j.ejps.2010.07.015.","journal-title":"Eur J Pharmaceut Sci"},{"issue":"8","key":"940_CR33","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/j.1552-4604.1993.tb05609.x","volume":"33","author":"DA Rushing","year":"1993","unstructured":"Rushing DA, Piscitelli SC, Rodvold KA, Tewksbury DA. The disposition of doxorubicin on repeated dosing. J Clin Pharmacol. 1993;33(8):698\u2013702. https:\/\/doi.org\/10.1002\/j.1552-4604.1993.tb05609.x.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"940_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.46542\/pe.2024.246.105115","volume":"24","author":"TP Rahmani","year":"2024","unstructured":"Rahmani TP, Harahap Y, Purwanto DJ. A review of the relationship between Doxorubicin and Doxorubicinol, CBR1 polymorphism, and cardiotoxicity. Pharmacy Ed. 2024;24(6):105\u201315. https:\/\/doi.org\/10.46542\/pe.2024.246.105115.","journal-title":"Pharmacy Ed"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00940-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00940-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00940-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T14:09:33Z","timestamp":1747318173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00940-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["940"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00940-9","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"5 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The authors did not receive support from any organization for the work reported in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"All procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the Ethics Committee of Hirosaki University Graduate School of Medicine (project identification code: 2018-055-4) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic Approval"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Informed consent for publication was obtained from all participants.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: TN; investigation: TT, YC, KS, KK, TT, and SY; measurement of anticancer drugs: JN, KU, and KS; formal analysis: KS; writing\u2014original draft preparation: KS; writing\u2014review and editing: AS, HS, and TN. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}